Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07389980 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

Study acronym: PALLAS
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
Trial Details
NCT Number NCT07389980
Lead Sponsor Yeungnam University College of Medicine
Collaborators: Bayer
Conditions
(from sponsor)		 Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Related terms Polypoidal Choroidal Vasculopathy
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov